Natixis’s Teladoc Health TDOC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.35M | Buy |
+158,900
| New | +$1.06M | 0.01% | 698 |
|
|
2026
Q1 | – | Sell |
-94,400
| Closed | -$661K | – | 1319 |
|
|
2025
Q4 | $661K | Buy |
+94,400
| New | +$739K | ﹤0.01% | 793 |
|
|
2025
Q1 | – | Sell |
-425
| Closed | -$3.86K | – | 1188 |
|
|
2024
Q4 | $3.86K | Hold |
425
| – | – | ﹤0.01% | 979 |
|
|
2024
Q3 | $3.9K | Buy |
425
+27
| +7% | +$223 | ﹤0.01% | 877 |
|
|
2024
Q2 | $3.89K | Sell |
398
-19,500
| -98% | -$238K | ﹤0.01% | 916 |
|
|
2024
Q1 | $300K | Buy |
+19,898
| New | +$361K | ﹤0.01% | 676 |
|
|
2023
Q3 | – | Sell |
-120,200
| Closed | -$3.04M | – | 1136 |
|
|
2023
Q2 | $3.04M | Buy |
120,200
+99,748
| +488% | +$2.51M | 0.02% | 360 |
|
|
2023
Q1 | $530K | Sell |
20,452
-8,314
| -29% | -$222K | ﹤0.01% | 607 |
|
|
2022
Q4 | $680K | Sell |
28,766
-623,053
| -96% | -$16.8M | ﹤0.01% | 681 |
|
|
2022
Q3 | $16.6M | Buy |
651,819
+503,193
| +339% | +$17.7M | 0.08% | 190 |
|
|
2022
Q2 | $4.93M | Sell |
148,626
-234,800
| -61% | -$9.97M | 0.02% | 451 |
|
|
2022
Q1 | $27.7M | Buy |
383,426
+7,028
| +2% | +$506K | 0.1% | 204 |
|
|
2021
Q4 | $34.6M | Sell |
376,398
-66,849
| -15% | -$7.99M | 0.12% | 154 |
|
|
2021
Q3 | $56.2M | Buy |
+443,247
| New | +$64.5M | 0.19% | 102 |
|
|
2021
Q2 | – | Sell |
-289,287
| Closed | -$52.6M | – | 1021 |
|
|
2021
Q1 | $52.6M | Buy |
289,287
+57,953
| +25% | +$13.4M | 0.17% | 122 |
|
|
2020
Q4 | $46.3M | Buy |
231,334
+56,667
| +32% | +$11.5M | 0.17% | 124 |
|
|
2020
Q3 | $38.3M | Buy |
174,667
+128,658
| +280% | +$27.2M | 0.28% | 91 |
|
|
2020
Q2 | $8.78M | Sell |
46,009
-31
| -0.1% | -$5.43K | 0.07% | 206 |
|
|
2020
Q1 | $7.14M | Sell |
46,040
-686
| -1% | -$79.8K | 0.06% | 232 |
|
|
2019
Q4 | $3.89M | Buy |
46,726
+430
| +0.9% | +$32.7K | 0.02% | 450 |
|
|
2019
Q3 | $3.13M | Buy |
46,296
+34,030
| +277% | +$2.24M | 0.02% | 429 |
|
|
2019
Q2 | $815K | Sell |
12,266
-11,943
| -49% | -$696K | 0.01% | 563 |
|
|
2019
Q1 | $1.3M | Sell |
24,209
-2,006
| -8% | -$122K | 0.01% | 545 |
|
|
2018
Q4 | $1.3M | Buy |
26,215
+4,363
| +20% | +$267K | 0.01% | 476 |
|
|
2018
Q3 | $1.89M | Buy |
+21,852
| New | +$1.56M | 0.01% | 488 |
|
|
2017
Q4 | – | Sell |
-6,693
| Closed | -$222K | – | 1158 |
|
|
2017
Q3 | $222K | Buy |
+6,693
| New | +$219K | ﹤0.01% | 1074 |
|
Other funds holding TDOC
VC
Natixis's TDOC Position: Q2 2026 in Review
Natixis opened a new position in Teladoc Health (TDOC) in Q2 2026: 158,900 shares worth $1.35M. The stake represents 0.01% of the portfolio and ranks #698 among its holdings. This is a return to the name: Natixis previously reported a position in TDOC as recently as Q4 2025.
Natixis first reported a position in TDOC in Q3 2017 and has held it in 26 quarters since. The position peaked at $56.2M in Q3 2021. 348 funds tracked by Wall St. Rank hold TDOC as of Q2 2026.
- Natixis held 158,900 shares of Teladoc Health worth $1.35M as of Q2 2026.
- Teladoc Health was a new Natixis position in Q2 2026.
- Teladoc Health made up 0.01% of Natixis's portfolio in Q2 2026, its #698 holding.
- Natixis first reported a position in Teladoc Health in Q3 2017 and has held it in 26 quarters since.
- Natixis's Teladoc Health position peaked at $56.2M in Q3 2021.
- 348 funds tracked by Wall St. Rank held Teladoc Health as of Q2 2026.
Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.